Santosh Kesari
A5063863193- Glioma Diagnosis and Treatment
- Brain Metastases and Treatment
- Cancer Research and Treatments
- Cancer Genomics and Diagnostics
- Immunotherapy and Immune Responses
- Virus-based gene therapy research
- Cancer Treatment and Pharmacology
- Radiomics and Machine Learning in Medical Imaging
- Cancer, Hypoxia, and Metabolism
- CAR-T cell therapy research
- Neuroblastoma Research and Treatments
- Sarcoma Diagnosis and Treatment
- Bone Tumor Diagnosis and Treatments
- RNA Interference and Gene Delivery
- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- Meningioma and schwannoma management
- Ubiquitin and proteasome pathways
- MicroRNA in disease regulation
- Histone Deacetylase Inhibitors Research
- Radiopharmaceutical Chemistry and Applications
- Viral Infectious Diseases and Gene Expression in Insects
- Protein Degradation and Inhibitors
Providence College
2018-2025
Pacific Heart Institute
2017-2025
Saint John's Health Center
2016-2025
Neurosciences Institute
2017-2025
Neuroscience Institute
2018-2025
University of California, San Diego
2015-2024
Ronald Reagan UCLA Medical Center
2024
University of North Carolina at Chapel Hill
2012-2024
University of California, Los Angeles
2020-2024
University of North Carolina Health Care
2024
<h3>Importance</h3> Glioblastoma is the most devastating primary malignancy of central nervous system in adults. Most patients die within 1 to 2 years diagnosis. Tumor-treating fields (TTFields) are a locoregionally delivered antimitotic treatment that interferes with cell division and organelle assembly. <h3>Objective</h3> To evaluate efficacy safety TTFields used combination temozolomide maintenance after chemoradiation therapy for glioblastoma. <h3>Design, Setting, Participants</h3> After...
Substantial data indicate that microRNA 21 (miR-21) is significantly elevated in glioblastoma (GBM) and many other tumors of various origins. This has been implicated aspects carcinogenesis, including cellular proliferation, apoptosis, migration. We demonstrate miR-21 regulates multiple genes associated with glioma cell migration, invasiveness, the RECK TIMP3 genes, which are suppressors malignancy inhibitors matrix metalloproteinases (MMPs). Specific inhibition antisense oligonucleotides...
Glioblastoma (GBM) is the most malignant brain tumor and highly resistant to intensive combination therapies anti-VEGF therapies. To assess resistance mechanism therapy, we examined vessels of GBMs in tumors that were induced by transduction p53 +/− heterozygous mice with lentiviral vectors containing oncogenes marker GFP hippocampus GFAP-Cre recombinase (Cre) mice. We surprised observe + vascular endothelial cells (ECs). Transplantation mouse GBM revealed tumor-derived (TDECs) originated...
Standard therapy for glioblastoma includes surgery, radiotherapy, and temozolomide. This Phase 3 trial evaluates the addition of an autologous tumor lysate-pulsed dendritic cell vaccine (DCVax®-L) to standard newly diagnosed glioblastoma.After surgery chemoradiotherapy, patients were randomized (2:1) receive temozolomide plus DCVax-L (n = 232) or placebo 99). Following recurrence, all allowed DCVax-L, without unblinding. The primary endpoint was progression free survival (PFS); secondary...
Abstract Glioblastoma, the most malignant type of primary brain tumor, is one solid cancers where cancer stem cells have been isolated, and studies suggested resistance those to chemotherapy radiotherapy. Here, we report establishment CSC-enriched cultures derived from human glioblastoma specimens. They grew as neurospheres in serum-free medium with epidermal growth factor fibroblast 2, varied level CD133 expression very efficiently formed highly invasive and/or vascular tumors upon...
Aberrant Notch signaling has been implicated in the pathogenesis of many human cancers. MK-0752 is a potent, oral inhibitor γ-secretase, an enzyme required for pathway activation. Safety, maximum-tolerated dose, pharmacokinetics (PKs), pharmacodynamics, and preliminary antitumor efficacy were assessed phase I study MK-0752.MK-0752 was administered three different schedules to patients with advanced solid tumors. Hair follicles collected at higher dose levels assess gene signature...
Glioblastoma cells secrete extra-cellular vesicles (EVs) containing microRNAs (miRNAs). Analysis of these EV miRNAs in the bio-fluids afflicted patients represents a potential platform for biomarker development. However, analytic algorithm quantitative assessment miRNA remains under-developed. Here, we demonstrate that reference transcripts commonly used PCR (including GAPDH, 18S rRNA, and hsa-miR-103) were unreliable assessing miRNA. In this context, quantitated absolute terms normalized...
MicroRNA (miRNA) expression profiling studies revealed a number of miRNAs dysregulated in the malignant brain tumor glioblastoma. Molecular functions these gliomagenesis are mainly unknown. We show that inhibition miR-10b, miRNA not expressed human and strongly upregulated both low-grade high-grade gliomas, reduces glioma cell growth by cell-cycle arrest apoptosis. These cellular responses mediated augmented direct targets including BCL2L11/Bim, TFAP2C/AP-2γ, CDKN1A/p21, CDKN2A/p16, which...
PURPOSE To assess efficacy and safety of single-agent bortezomib in previously untreated patients with multiple myeloma, investigate prevalence baseline treatment-emergent polyneuropathy, identify molecular markers associated response neuropathy. PATIENTS AND METHODS Patients received 1.3 mg/m(2) on days 1, 4, 8, 11, for up to eight 21-day cycles. A subset underwent neurophysiologic evaluation pre- post-treatment. Bone marrow aspirates were performed at exploratory whole-genome analyses....
The combination of galunisertib, a transforming growth factor (TGF)-β receptor (R)1 kinase inhibitor, and lomustine was found to have antitumor activity in murine models glioblastoma. Galunisertib (300 mg/day) given orally 14 days on/14 off (intermittent dosing). Lomustine as approved. Patients were randomized 2:1:1 ratio galunisertib + lomustine, monotherapy, or placebo lomustine. primary objective overall survival (OS); secondary objectives safety, pharmacokinetics (PKs), activity. One...
Glioblastoma is the most lethal primary brain cancer. Clinical outcomes for glioblastoma remain poor, and new treatments are needed.To investigate whether adding autologous tumor lysate-loaded dendritic cell vaccine (DCVax-L) to standard of care (SOC) extends survival among patients with glioblastoma.This phase 3, prospective, externally controlled nonrandomized trial compared overall (OS) in newly diagnosed (nGBM) recurrent (rGBM) treated DCVax-L plus SOC vs contemporaneous matched external...
To evaluate the results of randomized, double-blind, placebo-controlled phase II clinical trial ICT-107 in patients with newly diagnosed glioblastoma.We conducted a double-blinded randomized glioblastoma (GBM) and tested efficacy, safety, quality life (QoL), immune response. HLA-A1+ and/or -A2+-resected residual tumor ≤1 cm3 received radiotherapy concurrent temozolomide. Following completion radiotherapy, 124 patients, 2:1, [autologous dendritic cells (DC) pulsed six synthetic peptide...
Abstract Purpose: ANG1005, a novel taxane derivative, consists of three paclitaxel molecules covalently linked to Angiopep-2, designed cross the blood–brain and blood–cerebrospinal barriers penetrate malignant cells via LRP1 transport system. Preclinical clinical evidence efficacy with ANG1005 has been previously shown. Patients Methods: A multicenter, open-label phase II study in adult patients measurable recurrent brain metastases from breast cancer (BCBM), or without leptomeningeal...
Toca 511 (vocimagene amiretrorepvec) is an investigational nonlytic, retroviral replicating vector (RRV) that delivers a yeast cytosine deaminase, which converts subsequently administered courses of the prodrug FC (extended-release 5-fluorocytosine) into antimetabolite 5-fluorouracil. Forty-five subjects with recurrent or progressive high-grade glioma were treated. The end points this phase 1, open-label, ascending dose, multicenter trial included safety, efficacy, and molecular profiling;...